IL-15 mutant polypeptides as IL-15 antagonists and encoding nucleic acids
US10202433B2 · kind B2 · utility
3Cited by
0References
16Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Jun 27, 2014 |
| Grant date | Feb 12, 2019 |
| Priority date | — |
| Expiry date | Dec 11, 2034 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present relates to interleukin 15 (IL-15) antagonists and uses thereof, in particular for the treatment of autoimmune diseases and inflammatory diseases. In particular, the present invention relates to an IL-15 mutant polypeptide having the amino acid sequence as set forth in SEQ ID NO:1 wherein the leucine residue at position 45 is substituted by an aspartic acid residue, the asparagines residue at position 65 is substituted by a lysine residue and the leucine residue at position 69 is substituted by an arginine residue.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.